SG10201608485XA - (r) -nifuratel, its use for the treatment of infections and synthesis of (r) and (s) -nifuratel - Google Patents

(r) -nifuratel, its use for the treatment of infections and synthesis of (r) and (s) -nifuratel

Info

Publication number
SG10201608485XA
SG10201608485XA SG10201608485XA SG10201608485XA SG10201608485XA SG 10201608485X A SG10201608485X A SG 10201608485XA SG 10201608485X A SG10201608485X A SG 10201608485XA SG 10201608485X A SG10201608485X A SG 10201608485XA SG 10201608485X A SG10201608485X A SG 10201608485XA
Authority
SG
Singapore
Prior art keywords
nifuratel
infections
synthesis
treatment
Prior art date
Application number
SG10201608485XA
Inventor
Stefania Gagliardi
Alessandra Consonni
Federico Mailland
Anna Bulgheroni
Original Assignee
Polichem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47846051&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201608485X(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Polichem Sa filed Critical Polichem Sa
Publication of SG10201608485XA publication Critical patent/SG10201608485XA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C241/00Preparation of compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C241/02Preparation of hydrazines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18Oxygen atoms
    • C07D263/20Oxygen atoms attached in position 2
    • C07D263/26Oxygen atoms attached in position 2 with hetero atoms or acyl radicals directly attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
SG10201608485XA 2012-05-11 2013-03-13 (r) -nifuratel, its use for the treatment of infections and synthesis of (r) and (s) -nifuratel SG10201608485XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20120167640 EP2662371A1 (en) 2012-05-11 2012-05-11 (R)-Nifuratel and synthesis of (R) and (S)-Nifuratel

Publications (1)

Publication Number Publication Date
SG10201608485XA true SG10201608485XA (en) 2016-12-29

Family

ID=47846051

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201406447SA SG11201406447SA (en) 2012-05-11 2013-03-13 (r) -nifuratel, its use for the treatment of infections and synthesis of (r) and (s) -nifuratel
SG10201608485XA SG10201608485XA (en) 2012-05-11 2013-03-13 (r) -nifuratel, its use for the treatment of infections and synthesis of (r) and (s) -nifuratel

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201406447SA SG11201406447SA (en) 2012-05-11 2013-03-13 (r) -nifuratel, its use for the treatment of infections and synthesis of (r) and (s) -nifuratel

Country Status (27)

Country Link
US (2) US9284306B2 (en)
EP (2) EP2662371A1 (en)
JP (1) JP2015515998A (en)
KR (1) KR20150008871A (en)
CN (1) CN104379580A (en)
AU (1) AU2013258385A1 (en)
BR (1) BR112014027953A2 (en)
CA (1) CA2869827A1 (en)
CL (1) CL2014002951A1 (en)
CO (1) CO7131368A2 (en)
CR (1) CR20140505A (en)
DO (1) DOP2014000252A (en)
EA (1) EA201492081A1 (en)
EC (1) ECSP14026432A (en)
GE (2) GEP201706626B (en)
HK (1) HK1202539A1 (en)
IL (1) IL235429A0 (en)
IN (1) IN2014DN09256A (en)
MA (1) MA20150279A1 (en)
MX (1) MX2014013759A (en)
NZ (1) NZ700752A (en)
PE (1) PE20150167A1 (en)
PH (2) PH12014502500A1 (en)
SG (2) SG11201406447SA (en)
TN (1) TN2014000430A1 (en)
WO (1) WO2013167295A1 (en)
ZA (1) ZA201407596B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108254453A (en) * 2016-12-28 2018-07-06 苏州电器科学研究院股份有限公司 A kind of effective detection method for measuring phthalic acid ester content in plastic products
IL302943A (en) 2017-09-20 2023-07-01 Ph Pharma Co Ltd Thailanstatin analogs
CN108760950B (en) * 2018-04-25 2022-07-15 国检测试控股集团京诚检测有限公司 Method for determining nitrofuran metabolite
CN111892557B (en) * 2019-05-05 2022-11-08 河北圣泰材料股份有限公司 Synthetic method of piperazine film-forming ionic liquid
CN110672765B (en) * 2019-10-11 2022-03-18 温州海鹤药业有限公司 Method for quantitatively detecting cis-isomer impurities in nifuratel
CN112457304B (en) * 2020-12-07 2022-03-11 中国药科大学 Preparation method of nifuratel
CN113828243B (en) * 2021-09-14 2022-06-28 南京南大药业有限责任公司 Method and equipment for manufacturing nifuratel nystatin suppository

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE635608A (en) 1962-08-01
CN100506820C (en) 2006-03-16 2009-07-01 韩志强 (S)-nifuratel, preparation method and application thereof
CN100516063C (en) * 2006-03-16 2009-07-22 韩志强 Production method of nifuratel
CN101434584A (en) * 2007-11-15 2009-05-20 中山大学 Chiral oxazolidinone compound with antibacterial activity
EP2243482A1 (en) * 2009-04-20 2010-10-27 Polichem SA Use of nifuratel to treat infections caused by atopobium species

Also Published As

Publication number Publication date
SG11201406447SA (en) 2014-11-27
AU2013258385A1 (en) 2014-10-30
HK1202539A1 (en) 2015-10-02
DOP2014000252A (en) 2014-12-31
PH12014502500B1 (en) 2014-12-15
ECSP14026432A (en) 2015-09-30
US20150119431A1 (en) 2015-04-30
JP2015515998A (en) 2015-06-04
BR112014027953A2 (en) 2018-02-06
MX2014013759A (en) 2015-08-07
KR20150008871A (en) 2015-01-23
PH12015502241A1 (en) 2016-08-15
US9067927B2 (en) 2015-06-30
MA20150279A1 (en) 2015-08-31
EA201492081A1 (en) 2015-06-30
CR20140505A (en) 2015-02-06
NZ700752A (en) 2016-02-26
PH12014502500A1 (en) 2014-12-15
IL235429A0 (en) 2014-12-31
ZA201407596B (en) 2016-05-25
CO7131368A2 (en) 2014-12-01
EP2662371A1 (en) 2013-11-13
IN2014DN09256A (en) 2015-07-10
US20150148547A1 (en) 2015-05-28
WO2013167295A1 (en) 2013-11-14
TN2014000430A1 (en) 2016-03-30
GEP201706626B (en) 2017-02-10
GEP201606595B (en) 2017-01-10
PE20150167A1 (en) 2015-02-07
EP2847189A1 (en) 2015-03-18
CN104379580A (en) 2015-02-25
CL2014002951A1 (en) 2014-12-26
CA2869827A1 (en) 2013-11-14
US9284306B2 (en) 2016-03-15

Similar Documents

Publication Publication Date Title
ZA202003200B (en) Compositions, methods, and systems for the synthesis and use of imaging agents
HK1218110A1 (en) Sulfamoyl arylamides and the use thereof as medicaments for the treatment of hepatitis b
ZA201500921B (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diaseases
HK1211589A1 (en) Compounds for the treatment of paramoxyvirus viral infections
ZA201405820B (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
HK1210030A1 (en) Sulfamoyl aryamides and the use thereof as medicaments for the treatment of hepatitis b
EP2675469A4 (en) Compositions, devices and methods of use thereof for the treatment of cancers
SG2014008304A (en) C10rf32 antibodies, and uses thereof for treatment of cancer
HK1220324A1 (en) Methods, compounds, and compositions for the treatment of angiotensin-related diseases
EP3068442A4 (en) Bionanofluid for use as a contrast, imaging, disinfecting and/or therapeutic agent
IL235429A0 (en) (r)-nifuratel, its use for the treatment of infections and synthesis of (r) and (s)-nifuratel
EP2867239A4 (en) Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes
HRP20181879T1 (en) Compounds for the treatment of obesity and methods of use thereof
EP3015077A4 (en) Treatment instrument for endoscope, and endoscope system
AP2015008338A0 (en) Compounds for the treatment and prevention of retroviral infections
HK1206348A1 (en) Cyclohexane-1,2-indene-1,2-imidazol compounds and their use as bace inhibitors -12--12- bace
HK1246694A1 (en) Use of thymosin alpha for the treatment of sepsis
EP3044321A4 (en) New marker for the classification, diagnosis and treatment of scoliosis
EP2800568A4 (en) Compositions, methods of use, and methods of treatment
ZA201408065B (en) Compositions and methods for the treatment of diabetes
PL2855475T3 (en) Alpha-carbolines for the treatment of cancer
HK1210421A1 (en) Use of pregn-4-en-20-yn-3-one for the treatment of depressive disorders -4--20--3-
IL232339A0 (en) C10rf32 antibodies , and uses thereof for treatment of cancer
GB201208770D0 (en) Compounds for use in the treatment of adenovirus infections
AU2013900781A0 (en) Nacre-like composites, methods of synthesis and methods of use